Giovanna Finocchiaro
IRCCS Humanitas Research Hospital · 133 works · 4,767 citations · h-index 31
Top works
- Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
- COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
- Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial
- EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
- Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography
- MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients
- Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
- Role of gemcitabine in cancer therapy
- EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer
- Clinical Implications of KRAS Mutations in Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Important Role for Mutations in Minor Clones
- Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib
- EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
- Clinical experience with gefitinib: An update
- Levocarnitine Administration in Elderly Subjects with Rapid Muscle Fatigue
- Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer
- L-Carnitine in the Treatment of Mild or Moderate Hepatic Encephalopathy
- Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients
- Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
- Increased SOX2 Gene Copy Number Is Associated with FGFR1 and PIK3CA Gene Gain in Non-Small Cell Lung Cancer and Predicts Improved Survival in Early Stage Disease
- Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC)